With the American Society for Clinical Oncology annual meeting on the near horizon, cancer is dominating pharma news flow. This week, two FDA approvals brought the spotlight back to a familiar space: immuno-oncology.
Bristol-Myers Squibb Co.'s Opdivo (nivolumab) solidified its dominant position in the immune checkpoint inhibitor market with the May 17...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?